Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Methylphenidate
Methylphenidate for ADHD in Children and Adolescents: Modest Symptom Gains but Uncertain Net Benefit
Posted innews Pediatrics Psychiatry

Methylphenidate for ADHD in Children and Adolescents: Modest Symptom Gains but Uncertain Net Benefit

Posted by MedXY By MedXY 12/16/2025
Updated Cochrane analysis (212 RCTs, 16,302 participants) finds methylphenidate may reduce teacher-rated ADHD symptoms and improve general behaviour but increases non‑serious adverse events; overall evidence certainty is very low.
Read More
Evaluating Methylphenidate for Fatigue Management in Advanced Cancer: Insights from the MePFAC Randomized Controlled Trial
Posted inInternal Medicine Oncology Specialties

Evaluating Methylphenidate for Fatigue Management in Advanced Cancer: Insights from the MePFAC Randomized Controlled Trial

Posted by MedXY By MedXY 10/21/2025
The MePFAC trial demonstrates that methylphenidate is safe but does not significantly reduce fatigue compared to placebo in advanced cancer patients receiving palliative care, challenging previous assumptions about its efficacy.
Read More
  • SAIA-MH Strategy Boosts Mental Health Outcomes in Mozambique: A Breakthrough in Low-Resource Settings
  • Low-Calorie, Low-Protein Feeding in Shock: No Harm to Kidneys, NUTRIREA-3 Analysis Confirms
  • Language Barriers and Delirium Detection: Study Reveals Critical Disparities in ICU Care for Spanish-Speaking Patients
  • Observation Reduces CT Use in Pediatric Blunt Abdominal Trauma Without Missing Critical Injuries
  • Digital Mental Health Interventions Show Promise for Black and Female Health Care Workers
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in